Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal

BACKGROUND/AIMS: We studied the role of lysyl oxidase-like 2 (LOXL2) in collagen crosslinking and hepatic progenitor cell (HPC) differentiation, and the therapeutic efficacy of a LOXL2-blocking monoclonal antibody on liver fibrosis progression/reversal in mice. METHODS: Anti-LOXL2 antibody, control...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikenaga, Naoki, Peng, Zhen-Wei, Vaid, Kahini A, Liu, Susan B, Yoshida, Shuhei, Sverdlov, Deanna Y, Mikels-Vigdal, Amanda, Smith, Victoria, Schuppan, Detlef, Popov, Yury V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561383/
https://www.ncbi.nlm.nih.gov/pubmed/28073888
http://dx.doi.org/10.1136/gutjnl-2016-312473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561383/
https://www.ncbi.nlm.nih.gov/pubmed/28073888
http://dx.doi.org/10.1136/gutjnl-2016-312473

Ejemplares similares